On December 20, 2018, Akorn, Inc. announced that Douglas S. Boothe was named President and Chief Executive Officer of the company, effective January 1, 2019. Mr. Boothe most recently served as president of the $600 million generics division of publicly held Impax Laboratories. Prior to Impax Laboratories, Mr. Boothe was the executive vice president and general manager of Perrigo Company Plc, with responsibility for the approximately $1 billion U.S. pharmaceuticals business, which included generics and specialty pharmaceutical products.